世界の多形性膠芽腫（GBM）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2584 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、多形性膠芽腫（GBM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、標的薬物療法、放射線療法）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・多形性膠芽腫（GBM）治療の市場動向 ・企業の競争状況、市場シェア ・多形性膠芽腫（GBM）治療の種類別市場規模（化学療法、標的薬物療法、放射線療法） ・多形性膠芽腫（GBM）治療の用途別市場規模（病院、クリニック、その他） ・多形性膠芽腫（GBM）治療の北米市場規模2016-2027（アメリカ、カナダ） ・多形性膠芽腫（GBM）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・多形性膠芽腫（GBM）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・多形性膠芽腫（GBM）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・多形性膠芽腫（GBM）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceuticals、Teva Pharmaceutical、Emcure Pharmaceuticals） ・結論

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline.
North America dominated the global market in 2017, accounting for over 35% share in terms of revenue. Europe was another major market for glioblastoma multiforme (GBM) therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe.

Market Analysis and Insights: Global Glioblastoma Multiforme (GBM) Therapeutics Market
The global Glioblastoma Multiforme (GBM) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Glioblastoma Multiforme (GBM) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Glioblastoma Multiforme (GBM) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Glioblastoma Multiforme (GBM) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Glioblastoma Multiforme (GBM) Therapeutics market.

Global Glioblastoma Multiforme (GBM) Therapeutics Scope and Market Size
Glioblastoma Multiforme (GBM) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glioblastoma Multiforme (GBM) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Targeted Drug Therapy
Radiation Therapy

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Targeted Drug Therapy
1.2.4 Radiation Therapy
1.3 Market by Application
1.3.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Perspective (2016-2027)
2.2 Glioblastoma Multiforme (GBM) Therapeutics Growth Trends by Regions
2.2.1 Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Glioblastoma Multiforme (GBM) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Glioblastoma Multiforme (GBM) Therapeutics Industry Dynamic
2.3.1 Glioblastoma Multiforme (GBM) Therapeutics Market Trends
2.3.2 Glioblastoma Multiforme (GBM) Therapeutics Market Drivers
2.3.3 Glioblastoma Multiforme (GBM) Therapeutics Market Challenges
2.3.4 Glioblastoma Multiforme (GBM) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue
3.1.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Glioblastoma Multiforme (GBM) Therapeutics Revenue
3.4 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio
3.4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2020
3.5 Glioblastoma Multiforme (GBM) Therapeutics Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Type
4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Application
5.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
6.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
6.2.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
6.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
6.3.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
6.4 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
6.4.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
7.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
7.2.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
7.3.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
7.4.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
9.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
9.2.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
9.3.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
9.4.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.1.4 Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.2.4 Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Details
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.4.4 Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.5.4 AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.5.5 AbbVie Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.6.4 Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Sun Pharmaceuticals
11.8.1 Sun Pharmaceuticals Company Details
11.8.2 Sun Pharmaceuticals Business Overview
11.8.3 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.8.4 Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.8.5 Sun Pharmaceuticals Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Details
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.9.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Emcure Pharmaceuticals
11.10.1 Emcure Pharmaceuticals Company Details
11.10.2 Emcure Pharmaceuticals Business Overview
11.10.3 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.10.4 Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
11.10.5 Emcure Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Drug Therapy
Table 4. Key Players of Radiation Therapy
Table 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2022-2027)
Table 11. Glioblastoma Multiforme (GBM) Therapeutics Market Trends
Table 12. Glioblastoma Multiforme (GBM) Therapeutics Market Drivers
Table 13. Glioblastoma Multiforme (GBM) Therapeutics Market Challenges
Table 14. Glioblastoma Multiforme (GBM) Therapeutics Market Restraints
Table 15. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2020)
Table 18. Ranking of Global Top Glioblastoma Multiforme (GBM) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service
Table 22. Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Glioblastoma Multiforme (GBM) Therapeutics Product
Table 65. Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Glioblastoma Multiforme (GBM) Therapeutics Product
Table 70. Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Roche Recent Development
Table 72. Arbor Pharmaceuticals Company Details
Table 73. Arbor Pharmaceuticals Business Overview
Table 74. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product
Table 75. Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Arbor Pharmaceuticals Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Product
Table 80. Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. AbbVie Company Details
Table 83. AbbVie Business Overview
Table 84. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Product
Table 85. AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 86. AbbVie Recent Development
Table 87. Amgen Company Details
Table 88. Amgen Business Overview
Table 89. Amgen Glioblastoma Multiforme (GBM) Therapeutics Product
Table 90. Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Amgen Recent Development
Table 92. Bristol-Myers Squibb Company Details
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Product
Table 95. Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Sun Pharmaceuticals Company Details
Table 98. Sun Pharmaceuticals Business Overview
Table 99. Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Sun Pharmaceuticals Recent Development
Table 101. Teva Pharmaceutical Company Details
Table 102. Teva Pharmaceutical Business Overview
Table 103. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Product
Table 104. Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Teva Pharmaceutical Recent Development
Table 106. Emcure Pharmaceuticals Company Details
Table 107. Emcure Pharmaceuticals Business Overview
Table 108. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product
Table 109. Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021) & (US$ Million)
Table 110. Emcure Pharmaceuticals Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Targeted Drug Therapy Features
Figure 4. Radiation Therapy Features
Figure 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Glioblastoma Multiforme (GBM) Therapeutics Report Years Considered
Figure 10. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players in 2020
Figure 15. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2020
Figure 17. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region (2016-2027)
Figure 39. China Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Merck Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 59. Roche Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 60. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 62. AbbVie Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 63. Amgen Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 65. Sun Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 66. Teva Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 67. Emcure Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---